null

null

null

null

null

null

null

null

null

Minimal debt; cash-funded operations with ~$200M cash runway; 20% rate rise has negligible interest expense impact given near-zero leverage.

Low sensitivity; no significant floating-rate debt; higher rates increase opportunity cost of cash reserves but do not impair debt service.

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Single-source biologics CDMO reliance (likely Catalent/Samsung Biologics); Chinese API precursor sourcing for monoclonal antibody inputs.

Minimal international revenue as of 2024; no material sovereign currency devaluation exposure; U.S.-centric commercialization only.

Predominantly U.S.-only revenue footprint; no meaningful ex-U.S. commercial presence; currency devaluation risk effectively zero.

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High; single CDMO manufacturing partner for VYD222 represents non-substitutable critical path; switching cost is 12–18 months minimum.

Biopharmaceutical product company; cloud disruption would impair operations but not directly destroy product; 30-day migration feasible for data systems.

Secondary R&D and clinical data management on cloud; disruption delays trials but core IP (antibodies) is not cloud-dependent.

Moderate API coupling risk in clinical data platforms (Medidata, Veeva); proprietary antibody discovery platform has low external API dependency.

Low Howey risk; revenue derived from drug product sales/government contracts, not investment schemes; equity is standard security, not a token.

Very High

Moderate GDPR/CCPA exposure via clinical trial patient data; U.S.-focused trials reduce GDPR scope; CCPA compliance standard for biotech.

Low antitrust risk; niche COVID-19 antibody market with minimal market share; no dominant position warranting regulatory scrutiny.

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Nearly 100% transactional; revenue tied to U.S. government procurement contracts (BARDA) and product sales; no recurring subscription model.

Government contract procurement (BARDA/HHS) and commercial hospital/pharmacy sales of monoclonal antibody VYD222 for COVID-19.

Government-negotiated contract pricing limits upside; commercial pricing constrained by payer formulary and competing COVID therapies (Paxlovid).

Low to moderate; price-taker in government procurement; commercial pricing subject to insurance reimbursement and generic/branded competition.

Estimated 60–75% gross margin at scale for biologics; current margins depressed by low volume and high fixed CDMO costs.

No free-rider problem; product is a regulated prescription biologic requiring purchase; no freemium or open-access model exists.

Sublinear headcount growth potential; manufacturing outsourced to CDMO; revenue scaling primarily requires commercial and regulatory staff additions.

Marginal cost of revenue growth is CDMO batch production cost; doubling revenue does not require doubling headcount given outsourced manufacturing.

Not applicable; Invivyd operates no franchise network.

At 10x scale, CAC likely falls as government contract vehicles lower per-unit acquisition cost; but market size (immunocompromised COVID patients) constrains addressability.

No network effects; biologic drug efficacy and adoption are independent of user base size; classic pipeline biotech model.

AI displacement risk low for core antibody discovery; AI may accelerate variant monitoring and antibody engineering, representing opportunity not threat.

Moderate resilience; government-funded contracts provide stability, but commercial demand for COVID prophylactics is discretionary and pandemic-cycle dependent.

U.S. federal government (HHS/BARDA) — high concentration risk; single customer (government) likely represents majority of near-term revenue.

Immunocompromised patients via specialty pharmacy and hospital channels; commercially nascent segment with high reimbursement dependency.

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

0.3% CapEx / Revenue (Low-CapEx Asset-Light)

0001832038

IVVD